Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer (Q36607936)

15 August 2017

title

Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer (English)

1 reference

15 August 2017

1 reference

Ross C Semeniuk

1

1 reference

15 August 2017

Peter M Venner

series ordinal

2

1 reference

15 August 2017

Scott North

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

68

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

565-569

1 reference

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Clinical Observations on the Doubling Time of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prostate-specific antigen doubling time predicts disease progression and survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.03.055

10.1016/J.UROLOGY.2006.03.055

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference